Transrectal ultrasound examination of prostate cancer guided by fusion imaging of multiparametric MRI and TRUS: avoiding unnecessary mpMRI-guided targeted biopsy / 亚洲男科学杂志(英文版)

The purpose of this study was to explore transrectal ultrasound (TRUS) findings of prostate cancer (PCa) guided by multiparametric magnetic resonance imaging (mpMRI) and to improve the Prostate Imaging Reporting and Data System (PI-RADS) system for avoiding unnecessary mpMRI-guided targeted biopsy (TB). From January 2018 to October 2019, fusion mpMRI and TRUS-guided biopsies were performed in 162 consecutive patients. The study included 188 suspicious lesions on mpMRI in 156 patients, all of whom underwent mpMRI-TRUS fusion imaging-guided TB and 12-core transperineal systematic biopsy (SB). Univariate analyses were performed to investigate the relationship between TRUS features and PCa. Then, logistic regression analysis with generalized estimating equations was performed to determine the independent predictors of PCa and obtain the fitted probability of PCa. The detection rates of PCa based on TB alone, SB alone, and combined SB and TB were 55.9% (105 of 188), 52.6% (82 of 156), and 62.8% (98 of 156), respectively. The significant predictors of PCa on TRUS were hypoechogenicity (odds ratio [OR]: 9.595, P = 0.002), taller-than-wide shape (OR: 3.539, P = 0.022), asymmetric vascular structures (OR: 3.728, P = 0.031), close proximity to capsule (OR: 3.473, P = 0.040), and irregular margins (OR: 3.843, P = 0.041). We propose subgrouping PI-RADS score 3 into categories 3a, 3b, 3c, and 3d based on different numbers of TRUS predictors, as the creation of PI-RADS 3a (no suspicious ultrasound features) could avoid 16.7% of mpMRI-guided TBs. Risk stratification of PCa with mpMRI-TRUS fusion imaging-directed ultrasound features could avoid unnecessary mpMRI-TBs.

Predictive value of multiparametric MRI for prostate cancer pathology and tumor staging / 中国辐射卫生

Objective To evaluate the value of multiparametric MRI for prediction of prostate cancer pathology and tumor staging. Methods A total of 80 patients with prostate cancer admitted during the period from 2016 to 2021 were enrolled as the study subjects, and all patients underwent multiparametric MRI. The pathological examination of radical prostatectomy specimens was used as a gold standard to evaluate the predictive value of multiparametric MRI for significant prostate cancaer, extracapsular extension, index lesion location and lymph node metastasis. Results Multiparametric MRI showed a sensitive of 96%, specificity of 60%, positive predictive value of 97.3% and negative predictive value of 50% for prediction of significant prostate cancer, and the concordance between multiparametric MRI and pathology of radical prostatectomy specimens was 75% for prediction of index lesions. In addition, multiparametric MRI showed a 40% sensitivity, 91.4% specificity, 85.7% positive predictive value and 54.2% negative predictive value for identification of extracapsular extension and a 16.7% accuracy for detection of lymph node metastasis. Conclusion Multiparametric MRI is highly sensitive for predicting significant prostate cancer with a high positive predictive value and is highly accurate for identification of index lesions of prostate cancer, which is of great value to propose prostate cancer treatment schemes and evaluate the clinical prognosis among prostate cancer patients.

Concordance of multiparameteric MRI and MRI ultrasound fusion-guided prostate biopsy

@#Multiparametric MRI (mpMRI) of the prostate is recently becoming more and more utilized in the detection of prostate cancer. Studies have shown that a higher PIRADS score correlated to a higher chance of obtaining a clinically significant prostate cancer but few studies have correlated PIRADS score to a specific Gleason score.@*OBJECTIVE@#This study aimed to determine the concordance of PIRADS score to the Gleason score result of MRI ultrasound fusion-guided prostate biopsy.@*METHODS@#All patients who had at least a PIRADS 2 lesion on mpMRI and underwent MRI ultrasound fusion-guided biopsy of the prostate from August 2018 up to November 2019 at St. Luke’s Medical Center, Global City were included in the study. An ambispective collection of data was done until the ideal sample size of greater than 100 positive lesions was obtained, in order to derive concordance rate.@*RESULTS@#One hundred and sixty-two patients were included in the study with a total of 212 lesions analyzed. Forty three percent were benign while 57% were found to be malignant. PIRADS 2 lesions had zero high grade cancers, and the percentage steadily increased with 37.8% of PIRADS lesions considered high grade. Concordance was computed to be 0.38 showing a fair, direct concordance between PIRADS and Gleason score with significant result (p<0.05).@*CONCLUSION@#A result of PIRADS 4 or 5 lesion on mpMRI will have a higher urgency of doing a prostate biopsy and subsequent management to prevent unfavorable outcomes as opposed to PIRADS 3 lesions.

Densidad de APE en pacientes PI-RADS 3: un parámetro clínico útil para su manejo / PSA density as a new approach for PIRADS 3 patient's management

Resumen: Objetivo: Analizar las biopsias realizadas en paciente categorizados PIRADS 3 en nuestra institución desde el segundo semestre del año 2016 al primer semestre del año 2018 y describir la correlación de la densidad de PSA con la incidencia de cáncer de próstata. Evaluar el rol de la densidad de PSA en la indicación de estudio histológico en pacientes PIRADS 3. Método: Trabajo autorizado por el comité de ética de nuestra institución. Se realizó búsqueda en el PACs, de todos los informes de RM multiparamétricas de próstata que incluyeran la categoría ¨PIRADS 3¨ en el periodo señalado. De ellos se calculó la densidad de PSA, con el último valor de PSA registrado en la ficha clínica previo a RM y volumen prostático en RM. Se procedió a buscar los pacientes con estudio histológico. Se correlacionó los resultados de biopsias con el valor de densidad de PSA. Realizamos análisis uni y multivariados, análisis estadísticos con sensibilidad, especificidad y uso de curva ROC. Resultados: De las 2416 RMmp de próstata realizadas en nuestra institución en las fechas ya descritas, se encontraron 424 informes catalogados con score PIRADS 3, y 267 de esos pacientes tenían estudio y seguimiento institucional, de los cuales 134 contaban con biopsia. La muestra tenía un promedio de edad de 60 años, y una mediana de densidad de PSA de 0,10 (RIC 0,07-0,14). Se encontraron 36 biopsias con cáncer clínicamente significativo (Gleason > 6), lo que corresponde a 26,8% de la muestra, valor similar al encontrado en la literuatua. En estos pacientes se obtuvo un punto de corte óptimo de densidad de PSA de 0,11, con una sensibilidad y especificidad de 67% y un AUC de 0,68. Una densidad de PSA de 0,11 presenta un OR de 4,1, con una probabilidad de 4 veces más de encontrar un cáncer de próstata por sobre este valor (IC 95% 1,3-9,8), lo cuál es estadísticamente significativo con un p igual a 0,01. Conclusión: La DAPE sobre 0,11 ng/ml/cc puede considerarse como una herramienta adicional para indicar biopsia en pacientes con RMmp PI-RADS 3, aumentando la precisión para la detección de cáncer de próstata clínicamente significativos ayudando a disminuir estudios histológicos innecesarios.

Abstract: Objective: To analyze the biopsies performed in patients categorized PIRADS 3 in our institution from the second half of 2016 to the first half of 2018 and describe the correlation of PSA density with the incidence of prostate cancer. To evaluate the role of PSA density in the indication of histological study in PIRADS 3 patients. Method: Work authorized by the ethics committee of our institution. The PACs were searched for all multiparameter prostate MRI reports that included the category "PIRADS 3" in the period indicated. The PSA density was calculated, with the last PSA value recorded in the clinical record before MRI and prostate volume in MRI. We proceeded to look for patients with the histological study. The biopsy results were correlated with the PSA density value. We perform uni and multivariate analyzes, statistical analyzes with sensitivity, specificity and use of the ROC curve. Results: Of the 2416 RMmp of the prostate performed in our institution on the dates already described, 424 reports catalogued with PIRADS 3 score were found, and 267 of those patients had study and institutional follow-up, of which 134 had a biopsy. The sample had an average age of 60 years and a median PSA density of 0.10 (RIC 0.075-0.146). We found 36 biopsies with clinically significant cancer (Gleason> 6), which corresponds to 26.8% of the sample, a value similar to that found in the literature. In these patients, an optimal cut-off point of PSA density of 0.11 was obtained, with a sensitivity and specificity of 67% and an AUC of 0.68. A PSA density of 0.11 has an OR of 4.1, with a 4-fold probability of finding prostate cancer above this value (95% CI 1.3-9.8), which It is statistically significant with a p equal to 0.01. Conclusion: DAPE over 0.11 ng/ml/cc can be considered as an additional tool to indicate biopsy in patients with RMmp PI-RADS 3, increasing the accuracy for the detection of clinically significant prostate cancer helping to reduce unnecessary histological studies.

Differences in negative predictive value of prostate MRI based in men with suspected or known cancer / Diferenças no valor preditivo negativo da ressonância magnética da próstata baseada em homens com câncer suspeito ou conhecido

Abstract Objective: To compare the negative predictive value (NPV) of multiparametric MRI for Gleason score (GS) ≥ 3+4 cancer and evaluate predictors of these tumors in men with suspected disease and under active surveillance (AS). Materials and Methods: This retrospective study included 38 men with suspected prostate cancer and 38 under AS with scans assigned PI-RADS v2 scores 1 or 2 between May 2016 and September 2017. Biopsy results were no cancer, GS = 3+3, or GS ≥ 3+4. Pre-MRI PSA, gland volume, and PSA density were recorded. Chi-square, equality of proportions, and logistic regressions were used to analyze the data. Results: Intermediate to high-grade cancer was found in 12.8% (95% CI = 2.3-23.3) and 35.9% (95% CI = 20.8-50.9) of men with suspected cancer, and under AS (p = 0.02), respectively. The NPV for GS ≥ 3+4 were 87.2% (suspected cancer; 76.7-97.7) and 64.1% (AS; 49.0-79.2). In neither group PSA significantly predicted cancer grade (p = 0.75 and 0.63). Although it did not reach conventional statistical significance, PSA density was a good predictor of cancer grade in men with suspected disease (p = 0.06), but not under AS (p = 0.62). Conclusion: The NPV of multiparametric MRI for GS ≥ 3+4 is higher in men with suspected prostate cancer than in men under AS. PSA density ≤ 0.15 improved the prediction of intermediate to high-grade disease in patients without known cancer.

Resumo Objetivo: Comparar o valor preditivo negativo (VPN) da RM multiparamétrica da próstata para o diagnóstico de tumores escore de Gleason (EG) ≥ 3+4 e avaliar os preditores desses tumores em homens com suspeita de doença e nos sob vigilância ativa (VA). Materiais e Métodos: Este estudo retrospectivo incluiu 38 homens com suspeita de câncer de próstata e 38 em VA com RM, aos quais foram atribuídos escores PI-RADS v2 1 ou 2 entre maio de 2016 e setembro de 2017. Os resultados da biópsia foram ausência de câncer, câncer EG = 3+3 ou câncer EG ≥ 3+4. PSA pré-RM, volume da glândula e densidade de PSA foram anotados. Qui-quadrado, igualdade de proporções e regressões logísticas foram utilizados para analisar os dados. Resultados: Câncer de grau intermediário a alto grau foi encontrado em 12,8% (IC 95% = 2,3-23,3) e 35,9% (IC 95% = 20,8-50,9) dos homens com suspeita de câncer e nos sob VA (p = 0,02), respectivamente. O VPN para GS ≥ 3+4 foi 87,2% (suspeita de câncer; IC 95% = 76,7-97,7) e 64,1% (VA; IC 95% = 49,0-79,2). Em nenhum dos grupos o PSA previu significativamente o grau de câncer (p = 0,75 e 0,63. Embora não tenha alcançado o limiar de significância estatística usual, a densidade de PSA foi um bom preditor de grau de câncer em homens com suspeita de doença (p = 0,06), mas não sob VA (p = 0,62). Conclusão: O VPN da RM multiparamétrica para GS ≥ 3+4 é maior em homens com suspeita de câncer de próstata do que em homens sob VA. Uma densidade de PSA ≤ 0,15 melhorou a previsão de doença de grau intermediário a alto grau em pacientes sem diagnóstico prévio de câncer.

Cáncer de próstata, el problema del diagnóstico: ¿es la resonancia multiparamétrica de próstata la solución? / Prostate cancer, the problem of diagnosis: is multiparametric prostate magnetic resonance imaging the solution?

Junto con un aumento sostenido en la incidencia de cáncer de próstata en los países desarrollados ha habido un cambio en el enfrentamiento diagnóstico en estos pacientes. El diagnóstico tradicional basado en la medición del antígeno prostático específico y la biopsia randomizada ha mostrado tener muchas falencias ya que sobre-diagnostica cánceres no significativos y sub-diagnostica cánceres clínicamente significativos. La resonancia magnética de próstata multiparamétrica ha demostrado ser útil ya que disminuye este tipo de falencias. En este artículo se revisará la historia de la resonancia magnética de próstata y del PI-RADS, con el objeto de revisar el rendimiento de estos métodos y sus indicaciones actuales.

Along with a sustained increase in the incidence of prostate cancer in developed countries, there has been a change in the diagnostic approach in these patients. The traditional diagnosis based on the measurement of the specific prostate antigen and randomized biopsy has shown to have many shortcomings as it leads to overdiagnosis of non-significant cancers and underdiagnosis of clinically significant cancers. The multiparametric prostate magnetic resonance imaging has proven to be useful since it diminishes these shortcomings. In this article we will review part of the history of prostate magnetic resonance imaging and PI-RADS, in order to review the performance of these methods and their current indications.

Comparative Diagnostic Test Accuracy of Multiparametric MRI versus CT Scan in Emergency Assessment of Patients with Suspected Acute Stroke

Background: The non-contrast computed tomography (CT) isa routine brain imaging modality for stroke diagnosis. However,the multiparametric magnetic resonance imaging (MRI) isincreasingly being used for acute stroke diagnosis owing to itsbetter sensitivity in detecting ischaemic brain infarcts.Objectives: To evaluate the best available evidence on thecomparative diagnostic test accuracies between CT andmultimodal MRI for the diagnosis of acute haemorrhagic andischaemic strokes in patients presenting to the emergencydepartment within 6 hours after the onset of stroke-likesymptoms.Methods: MEDLINE-Ovid, AMED, CINAHL and ENBASEelectronic bibliographic databases were searched in Englishfrom January 2004 to August 2014 and supplemented withmanual bibliographic hand search. Prospective andretrospective cohort studies, which directly compared thediagnostic test accuracies between CT (as reference standard)and DW-MRI or GRE-MRI in detecting ischaemic orhaemorrhagic stroke in the same patient population within 6hours after the onset of stroke-like symptoms, were consideredin the review. Only studies with diagnostic outcomes in termsof sensitivity and specificity of MRI versus CT in detectingacute stroke were considered. The quality of the selectedstudies in terms of risk of bias and clinical applicability wereappraised using the QUality Assessment of DiagnosticAccuracy Studies-2 (QUADAS-2) tool.Results: A total of 780 patients were evaluated in the fourselected cohort studies. Three and two studies contributeddata on the diagnosis of acute ICH and ischaemic stroke,respectively. Three studies were of good quality while one wasof poor quality. GRE-MRI exhibited high sensitivity of 83-100%(95% CI) in detecting acute ICH compared to 100% for CTused as the reference standard. CT exhibited poor sensitivity(12-81%) but better specificity (88-100%) in detecting acuteischaemic stroke as compared to DW-MRI, which had asensitivity of 73% (95% CI) and specificity of 92% (95% CI).Conclusions: It appears that GRE-MRI has comparablesensitivity as CT in detecting acute ICH. Similarly, DWI isexcellently sensitive and specific in detecting acute ischaemiclesions. These strongly suggest that MRI is sufficientlyaccurate for routine evaluation of patients with suspected acutestroke in the emergency setting. However, the studiesgenerally lack applicability aspects to the general populationand current clinical practice therefore, warranting furtherresearch. In the meantime, CT and/or MRI tests can be usedfor routine assessment of patients with suspected stroke in theemergency setting.

The clinical value of multiparametric-MRI in the diagnosis of bladder cancer / 实用医学杂志

Objective To investigate the value of multiparametric-MRI in predicting the T stage,the infil-tration,limitation and lymph node accuracy of bladder cancer. Methods A total of 55 patients underwent HR T2WI,DWI and DCE-MRI examination.The only diagnosis and the diagnosis combined diagnosis of bladder can-cer,tumor staging and infiltration were compared,and pathological diagnosis was used as the standard.ROC curve analysis was used to analyze the value of ADC in predicting the invasion of bladder cancer. Results There were 35 cases of stage T1,15 cases of stage T2,3 cases of stage T3 and 2 cases of stage T4.The accuracy of multipara-metric-MRI in staging of bladder cancer was 87.27%,which was better than that of DWI(80.00%),DCE-MRI (74.00%).HR-T2WI(K =0.768)has some advantages over DCE-MRI(k=0.545),DWI(k=0.648)and HR T2WI(k=0.280).The accuracy of multiparametric-MRI diagnosis of myasthenic invasive bladder cancer and localized bladder cancer was 87.27%,which was better than that of HR-T2WI,DWI and DCE-MRI.The AUC of ADC value was 0.989 for diagnosis of invasive bladder and 1.54 × 10-3mm2/s for diagnostic bladder cancer. The AUC of ROC curve for non-localized bladder cancer was 0.984 and the diagnostic cutoff point 1.42 × 10-3mm2/s. Conclusions The use of Multiparametric-MRI has high diagnostic performance in the diagnosis of bladder cancer in patients with T staging,myometrial invasion and tumor extent.

Accuracy of the multiparametric magnetic resonance imaging (MRI) and multiparametric MRI ultrasound cognitive fusion biopsy in the detection of prostate cancer among patients at a tertiary hospital

OBJECTIVE@#Image-guided targeted biopsy techniques have been proposed to address problems ofsystematic transrectal ultrasound guided prostate biopsies that lead to the suboptimal cancer detectionrate as well as inaccurate grading of the disease. This study aims to provide local data on the diagnosticaccuracy of multiparametric MRI (MP-MRI) and MP-MRI ultrasound cognitive fusion biopsy inidentifying areas of clinically significant malignancy of the prostate.@*MATERIALS AND METHODS@#This is a validity study involving patients who underwent MP-MRI and MP-MRI ultrasound cognitive fusion biopsy, who eventually underwent robot-assisted laparoscopic radicalprostatectomy (RALRP). Outcome measures included sensitivity, specificity, positive and negativepredictive values of MP-MRI and MP-MRI ultrasound cognitive fusion biopsy. Reference standardused was the final histopathologic report obtained after RALRP.@*RESULTS@#MP-MRI has a sensitivity of 35.5%, specificity of 95.2%, positive predictive value of 97.1%,and negative predictive value of 25%. MP-MRI ultrasound fusion biopsy had similar results, withsensitivity of 34.4%, specificity of 81.0%, positive predictive value of 88.9%, and negative predictivevalue of 21.8%.@*CONCLUSION@#The high specificity and positive predictive value of MP-MRI (95.2% and 97.1%respectively) indicates the necessity for a prostate biopsy and supports the utility of a targeted MP-MRI guided ultrasound cognitive fusion biopsy. However, the low sensitivity and negative predictivevalue (25% and 35% respectively) of 35.5% indicates that MP-MRI guidance does not limit thenumber of biopsy samples only to visible MP-MRI lesions, since negative areas on MP-MRI stillcontains tumors in 75% of cases.

Multiparametric MRI in the Detection of Clinically Significant Prostate Cancer

Prostate cancer is the most common cancer among men aged 50 years and older in developed countries and the third leading cause of cancer-related death in men. Multiparametric prostate MR imaging is currently the most accurate imaging modality to detect, localize, and stage prostate cancer. The role of multi-parametric MR imaging in the detection of clinically significant prostate cancer are discussed. In addition, insights are provided in imaging techniques, protocol, and interpretation.